Nasdaq vktx.

Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Viking Therapeutics, Inc. Common Stock (VKTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading ...Research Viking Therapeutics' (Nasdaq:VKTX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...

Dec 1, 2023 · Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various metabolic disorders.

About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell …

Look at Viking Therapeutics (NASDAQ:VKTX), for example.. This top biotech stock has been rocketing higher on the obesity story thanks to its VK2735 treatment.. Working much like Eli Lilly’s ...Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.Viking Therapeutics, Inc. (NASDAQ:VKTX) shares were also up, gaining 42% to $12.92 after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various ...Shares of NASDAQ VKTX opened at $13.01 on Monday. Viking Therapeutics has a 12 month low of $3.54 and a 12 month high of $25.72. The stock has a 50 day moving average of $10.86 and a 200-day ...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...

Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Apr 24, 2023 · Fintel reports that on April 25, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 29.59% Upside. As of ...

Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...VKTX Viking Therapeutics Options Ahead of Earnings Analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 11usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $1.80.Dec 1, 2023 · During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ... VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83. SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...In the news. Yahoo Finance. 3 days ago. Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.

Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ...Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...VFS. VinFast Auto Ltd. Ordinary Shares. $17.15 -0.84 -4.67%. Find the latest news headlines from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Rasi Bhadramani. Viking Therapeutics (NASDAQ:VKTX) has been my top NASH stock for the past few years due to VK2809's performance, the company's cash position, and the reasonable valuation ...SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...We believe that if VK2809 Ph2b biopsy-confirmed NASH trial outcome is sufficient to continue into Ph3 development, then we see VKTX’s current market cap as …

Find the latest Insider Activity data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Viking Therapeutics (NASDAQ: VKTX) stock is climbing higher on Tuesday after initiating a Phase 1 clinical trial of VK2735. VK2735 is a dual glucagon-like peptide 1 (GLP-1) and “glucose ...See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis.Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany ParticipantsStephanie Diaz - Manager of...Fintel reports that on July 27, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 141.43% Upside. As of ...

VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences.

Nov 28, 2023 · November 28, 2023. Technologies. In the last trading session, 1.46 million shares of the Viking Therapeutics Inc (NASDAQ:VKTX) were traded, and its beta was 0.61. Most recently the company’s share price was $12.00, and it changed around -$0.28 or -2.28% from the last close, which brings the market valuation of the company to $1.20B. Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ...Viking Therapeutics (NASDAQ: VKTX) Viking Therapeutics specializes in metabolic and endocrine illnesses. It has a robust pipeline of medications targeting muscle wasting, type 2 diabetes, hypertriglyceridemia, and other conditions. The biotech company is also working on treatments for metabolic and endocrine disorders.Dec 4, 2023 · The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01. Research Viking Therapeutics' (Nasdaq:VKTX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Shares of clinical-stage biotech Viking Therapeutics ( VKTX 6.68%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ...SAN DIEGO, CA – March 28, 2023 – Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company’s dual glucagon-like peptide 1 …Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...The latest price target for Viking Therapeutics ( NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target for 32.00 expecting VKTX to rise ...

(NASDAQ: VKTX) Viking Therapeutics's 52-week high was $25.72, and its 52-week low was $3.54. It is currently -49.42% from its 52-week high and 267.51% from its ...XBI, IMGN, VKTX, TGTX: ETF Outflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF ...Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. credit suisse stocksmost gainer stocks todaysil etfbest broker for crypto Find the latest Viking Therapeutics, Inc. (VKTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. itot dividend datesiem market size SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real... See more medical reits Oct 18, 2023 · Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of ... NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Forecast & Price Target $11.56 +0.21 (+1.85%) (As of 11/22/2023 ET) Compare Today's Range $11.21 $11.68 50 …5 Best Weight Loss Stocks To Invest In Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Call Transcript 10 Stocks Wall Street Analysts and Billionaires Are Crazy About 15 Best-Performing ...